Posted by Michael Wonder on 27 Mar 2023
Health Canada approves first treatment option for generalised pustular psoriasis flares in adults
24 March 2023 - In the EFFISAYIL-1 trial, over half of the Spevigo (spesolimab) treated patients were free of pustules, one week after receiving a single dose.
Health Canada has granted marketing authorisation for Spevigo (spesolimab for injection) for the treatment of flares in adult patients with generalised pustular psoriasis, Boehringer Ingelheim (Canada) has announced today.
